675 articles in this topic
A novel CTSL–Notch1–CUX1 pathway drives endothelial senescence and atherosclerotic plaque buildup, revealing fresh drug targets.
A post hoc analysis of the CLEAR Outcomes trial finds bempedoic acid significantly reduces DVT and pulmonary embolism risk.
A 48,904-patient meta-analysis finds prasugrel reduces heart attacks and stent clots better than its rivals after PCI.
A new JAMA Cardiology analysis warns that rising temperatures and a growing elderly population are converging to produce an unprecedented cardiac emergency.
A completed registry study identified and genotyped HoFH patients with LDLR mutations, laying groundwork for targeted gene therapy.
Akeso's AK102 faces a placebo-controlled test in high-cardiovascular-risk patients already on statins and ezetimibe.
A completed Phase IIIb trial tests whether pelacarsen can safely lower Lp(a) in historically underrepresented cardiovascular disease populations.
A phase 1 trial tests RBD7022, a novel subcutaneous RNA-based therapy, for safety and dosing in adults with high LDL cholesterol.
A 3-month interval cycling program assessed cardiovascular and metabolic improvements in obese vs. normal-weight women.
Experts propose that structured anticoagulation services offer a blueprint for broader cardiovascular medication stewardship programs.
A formal correction is issued to the landmark 2025 multi-society hypertension guidelines, ensuring clinical accuracy for practitioners.
A correction to a landmark study linking breast cancer to latent BMPR2-driven pulmonary hypertension susceptibility in Circulation.
